This Market Spotlight report covers the Chemotherapy-Induced Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The prevalence of CIA is difficult to determine due to inconsistencies in definition and variations in the severity of anemia, region, cancer type, and stage.
• Approved drugs in the cancer-related anemia space target erythropoietin receptor, transforming growth factor-beta and superfamily, angiogenesis, E3 ubiquitin ligase, and the immune system. The majority of marketed drugs are administered via the intravenous or subcutaneous routes, with one product being available in an oral formulation.
• The only industry-sponsored drug in active clinical development for cancer-related anemia is in Phase III. The only industry-sponsored drug in active clinical development for cancer-related anemia targets hypoxia-inducible factorprolyl hydroxylase. It is administered via the oral route.
• The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 23.7%, and the average probability a drug advances from Phase III is 83.3%. Drugs, on average, take 10.8 years from Phase I to approval, compared to 9.9 years in the overall hematology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
• Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
• Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson